Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma

Alvaro J. Alencar, Craig Moskowitz

Research output: Contribution to journalComment/debate


The addition of the immune-checkpoint inhibitor nivolumab to first-line therapy with doxorubicin, vinblastine and dacarbazine seems feasible, with no signals of severe additional toxicities emerging. The high response rates and acceptable safety profile might make this combination an appealing alternative in the treatment of patients with high-risk disease.

Original languageEnglish (US)
JournalNature Reviews Clinical Oncology
StatePublished - Jan 1 2019


ASJC Scopus subject areas

  • Oncology

Cite this